Junshi Biosciences Partners with Antengene on Novel Cancer Therapy Combination
Event summary
- Junshi Biosciences collaborates with Antengene to evaluate the combination of JS207 (PD-1/VEGF bispecific antibody) and ATG-037 (oral CD73 inhibitor) for solid tumors in China.
- JS207 has shown an objective response rate (ORR) of 58.1% in PD-L1 positive NSCLC patients as monotherapy.
- ATG-037 demonstrated ORRs of 33.3% in CPI-resistant melanoma and 21.4% in CPI-resistant NSCLC when combined with anti-PD-1 therapy.
- The collaboration aims to leverage complementary mechanisms targeting immune checkpoint signaling, angiogenesis, and adenosine pathways.
The big picture
This strategic collaboration between Junshi Biosciences and Antengene highlights a growing trend in oncology towards combination therapies that target multiple pathways simultaneously. The partnership aims to enhance therapeutic effects by combining immune checkpoint inhibition, anti-angiogenic activity, and adenosine pathway modulation, potentially offering more durable responses for patients with solid tumors.
What we're watching
- Clinical Efficacy
- How the combination of JS207 and ATG-037 will perform in clinical trials across multiple solid tumor types.
- Regulatory Progress
- The pace at which Junshi Biosciences advances its Phase 2/3 study for JS207 in NSCLC with FDA approval.
- Market Expansion
- Whether the collaboration can accelerate the development of innovative treatment options for patients in Chinese Mainland.
Related topics